Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher mean time to first relapse after induction of remission (weeks) at ≥… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Proportion of participants with success, defined as 0 to trace cells or 2‐step decrease in activity SUN‐grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in proportion of participants with success, defined as 0 to trace cells… (low certainty).
1 finding from 1 review
Intervention not reported
Risk of failure defined as 2‐step increase in activity in SUN grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in risk of failure defined as 2‐step increase in activity in SUN… (low certainty).
1 finding from 1 review